Skip to main content

Table 2 Background of the D2T RA cases after IPTW adjustment, by treatment types

From: Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

Numerical variable TNFi (N = 71) IL6-Ri (N = 78) CTLA4-Ig (N = 58) JAKi (N = 143) p
Mean SE Mean SE Mean SE Mean SE
Age 64.5 20.5 68.5 14.8 65.5 19.3 62.2 20.3 0.51
Disease duration (months) 169.1 135.7 171.7 129.3 191.8 152.7 167.5 131.5 0.18
CDAI 28.4 16.0 30.3 18.8 27.6 14.4 27.5 16.5 0.67
HAQ-DI 1.6 0.9 1.6 1.0 1.7 0.9 1.5 1.0 0.46
Dose of MTX (mg/week) 5.0 1.8 5.1 2.0 4.7 1.6 4.7 2.0 0.50
Dose of GC (mg/day)a 5.8 2.0 6.0 2.1 5.4 2.0 5.5 2.2 0.19
Serum creatinine (mg/dL) 0.9 0.7 0.9 0.8 0.7 0.4 0.7 0.4 0.10
  1. D2T RA difficult-to-treat rheumatoid arthritis, IPTW propensity-based inverse-probability treatment weighted, SE standard error, TNFi tumour necrosis factor inhibitor, IL-6Ri interleukin-6 receptor inhibitor, CTLA4-Ig cytotoxic T-lymphocyte–associated antigen-4 immunoglobulin, JAKi Janus kinase inhibitor, CDAI Clinical Disease Activity Index, HAQ-DI Health Assessment Questionnaire Disability Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS disease activity score, MTX methotrexate, GC glucocorticoid, ACPA anti-cyclic citrullinated peptide antibody